Document is current
Any future updates will be listed below
-
Authors
Ge, Huaixi
Liu, Changxue
Shen, Chengquan
Hu, Ding
Zhao, Xinzhao
Wang, Yanhua
Ge, Huimin
Qin, Ruize
Ma, Xiaocheng
Wang, Yonghua
-
Funding
Funding for this research was provided by:
National Key R&D Program of China (2023YFF0714404)
Taishan Scholar Program of Shandong Province (tsqn202306394)
- License Information
-
More Information
Article History
Received: 4 October 2024
Accepted: 11 February 2025
First Online: 28 February 2025
Declarations
:
: Research approval was obtained from the Ethics Committee of the Affiliated Hospital of Qingdao University.
: This multicenter, real-world study confirms that RC48 alone or in combination with PD-1 inhibitors exerted a promising effectiveness and manageable safety for first-line, second- and post-line, and neoadjuvant therapy with la/mUC. Interestingly, we found the heterogeneity of HER2 expression and followed up the patients rigorously. These findings may guide us to establish more standardized and rational HER2 scoring criteria to predict efficacy and screen potential beneficiary populations in clinical practice, contributing to the precision treatment of UC.
